- ISIN
- US80880X1046
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- IPO Date
- Apr 27, 2010
Highlights
- Market Cap
- $155.17M
- Enterprise Value
- -$3.37B
- EPS (TTM)
- -$303.01
- Total Revenue (TTM)
- $56.75M
- Gross Profit (TTM)
- $54.17M
- EBITDA (TTM)
- -$3.54B
- Year Range
- $0.24 - $2.60
- ROA (TTM)
- -55.68%
- ROE (TTM)
- -67.21%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SCNX Performance Chart
Scienture Holdings, Inc (SCNX) is down 25.1% since the beginning of the year. At $0 per share, SCNX is trading 85.3% below its 52-week high of $3. Investors who bought $1,000 worth of SCNX shares 5 years ago would now be looking at an investment worth $9.
Loading charts...
Returns By Period
Scienture Holdings, Inc (SCNX) has returned -25.12% so far this year and -58.09% over the past 12 months. Over the last ten years, SCNX has returned -38.89% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Scienture Holdings, Inc
- 1D
- 0.03%
- 1M
- -5.00%
- YTD
- -25.12%
- 6M
- -26.75%
- 1Y
- -58.09%
- 3Y*
- -58.28%
- 5Y*
- -61.19%
- 10Y*
- -38.89%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
SCNX Monthly Returns History
Based on dividend-adjusted daily data since Apr 27, 2010, SCNX's average daily return is +4.74%, while the average monthly return is +380.64%. At this rate, an investment would double in approximately 0.0 years.
Historically, 37% of months were positive and 63% were negative. The best month was May 2014 with a return of +73,650.0%, while the worst month was Jun 2011 at -63.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.
On a daily basis, SCNX closed higher 24% of trading days. The best single day was May 9, 2014 with a return of +14,900.0%, while the worst single day was Dec 1, 2011 at -76.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.92% | -5.33% | -33.74% | 37.19% | 5.63% | -7.53% | -25.12% | ||||||
| 2025 | -36.03% | -31.52% | -45.66% | -35.42% | -5.99% | 18.95% | 86.54% | -49.74% | -12.87% | -8.65% | -22.80% | -14.87% | -91.57% |
| 2024 | -19.75% | 128.30% | 61.11% | -41.80% | 10.23% | 70.02% | -7.13% | -18.39% | -4.05% | -3.03% | 0.00% | -17.69% | 86.89% |
| 2023 | 4.37% | -0.86% | -29.19% | 13.27% | -16.21% | 210.71% | -43.14% | 2.96% | -7.98% | -17.21% | 0.52% | -11.17% | -13.95% |
| 2022 | -13.98% | -13.30% | 57.39% | -38.63% | -8.92% | 4.62% | 2.47% | -30.12% | -2.59% | -21.24% | -36.52% | -28.74% | -82.94% |
| 2021 | 4.54% | 13.02% | -16.16% | -16.98% | -16.78% | 22.10% | 12.44% | 8.25% | -8.48% | -13.07% | -22.66% | -28.70% | -55.39% |
Benchmark Metrics
Scienture Holdings, Inc has an annualized alpha of 10936900.32%, beta of 0.48, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since April 27, 2010.
- This stock participated in 226.34% of S&P 500 Index downside but only 188.45% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.48 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 10,936,900.32%
- Beta
- 0.48
- R²
- 0.00
- Upside Capture
- 188.45%
- Downside Capture
- 226.34%
Return for Risk
Risk / Return Rank
SCNX ranks 48 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Scienture Holdings, Inc (SCNX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SCNX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.18 | ||
| Sortino ratioReturn per unit of downside risk | -0.69 | ||
| Omega ratioGain probability vs. loss probability | 1.31 | 1.37 | -0.06 |
| Calmar ratioReturn relative to maximum drawdown | -0.64 | 2.78 | -3.43 |
| Martin ratioReturn relative to average drawdown | -0.81 | 12.44 | -13.25 |
Dividends
Dividend History
Scienture Holdings, Inc provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2025 | 2024 |
|---|---|---|---|
| Dividend | $0.00 | $0.00 | $9.50 |
Dividend yield | 0.00% | 0.00% | 157.02% |
Monthly Dividends
The table displays the monthly dividend distributions for Scienture Holdings, Inc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2024 | $8.00 | $0.00 | $0.00 | $0.00 | $1.50 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $9.50 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Scienture Holdings, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Scienture Holdings, Inc was 99.85%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current Scienture Holdings, Inc drawdown is 99.77%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.85%Mar 2026 | 11y 10mo | — | 12y 23dJun 2014 - now |
2012 bear market2012 | -99.50%May 2012 | 2y 25d | 1y 11mo | 4y 10dApr 2010 - May 2014 |
Drawdown Indicators
| SCNX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.85% | -56.78% | -43.07% |
Max Drawdown (1Y)Largest decline over 1 year | -90.73% | -9.10% | -81.63% |
Max Drawdown (3Y)Largest decline over 3 years | -98.86% | -18.90% | -79.96% |
Max Drawdown (5Y)Largest decline over 5 years | -99.64% | -25.43% | -74.21% |
Max Drawdown (10Y)Largest decline over 10 years | -99.74% | -33.92% | -65.82% |
Current DrawdownCurrent decline from peak | -99.77% | -1.80% | -97.97% |
Average DrawdownAverage peak-to-trough decline | -81.80% | -10.71% | -71.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 71.44% | 2.03% | +69.41% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Scienture Holdings, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Scienture Holdings, Inc is priced in the market compared to other companies in the Pharmaceutical Retailers industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SCNX relative to other companies in the Pharmaceutical Retailers industry. Currently, SCNX has a P/S ratio of 1.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SCNX in comparison with other companies in the Pharmaceutical Retailers industry. Currently, SCNX has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SCNX
Add Scienture Holdings, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SCNX